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Abstract The objective of this study was to assess the in
vitro uterus relaxing potency of β2-adrenergic receptor (β2-
AR) agonists in pregnant rats after in utero administration of
the bacterial lipopolysaccharide, Escherichia coli endotoxin
(LPS). The LPS (100 μg/kg) was injected into the uterine
lumen on day 16 of pregnancy. The effects of β2-AR agonist
terbutaline was tested in vitro, in isolated uterine rings
precontracted by electric field stimulation. Uterine β2-AR
densities were detected by radioligand binding assay, the
activated G-protein levels were investigated by a radio-
labelled GTP binding assay. Uterine cAMP accumulation
and the serum tumor necrosis factor-α (TNF-α) levels were
measured by enzyme immunoassay. The endotoxin-evoked
preterm delivery occurred on day 21. Higher pD2 values of
terbutaline (p<0.001) were detected in endotoxin-treated
rats: 9.14±0.36 vs. 7.71±0.12 compared with sham-operated
rats. The densities or the equilibrium dissociation constants
of β2-ARs were not different (p>0.05) in LPS-treated vs.
control animals. Serum TNF-α level rose threefold after LPS
treatment, but this rise was abolished by thalidomide. In LPS +
thalidomide-treated rats, the effect of terbutaline became
similar to that in sham-operated controls. By the measure-
ment of myometrial cAMP levels, we documented that the
concentration–response curve of terbutaline on cAMP
accumulation was shifted to the left in the LPS-treated rats,
with a significant rise in the pD2. We concluded that in the
case of uterine inflammation, the in vitro uterus-relaxing
potency of β2-agonists enhances, which is possibly mediated
by TNF-α and uterine cAMP levels and that may serve as a
rationale for the use of β2-AR agonists in the attenuation of
preterm uterine contractions on an inflammatory basis.
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Introduction
Despite the broadly applied practice of aggressive tocolytic
therapy for women with preterm uterine contractions, the
incidence of preterm birth is stagnant or even increasing.
Although a wide variety of tocolytic agents are used
clinically, evidence regarding their efficacy is limited
(Berkman et al. 2003; Smith 2003). The strongest evidence,
in support of β2-adrenergic receptor (β2-AR) agonists,
suggest a reduction in delivery within 24–48 h, but rarely
further delay in delivery and no evident reductions in infant
morbidities. The lack of efficacy of tocolytic therapy may
be due, in part, to the wide range of factors that cause
preterm contractions (Garfield et al. 1998; Goldenberg et al.
2000; Challis et al. 2000, 2002; Wray et al. 2001) and
because tocolytic therapy does not actually treat any
underlying precipitating factors.
Intrauterine infection is present in approximately 25% of
all cases (Romero et al. 1988), and the earlier the
gestational age at delivery, the higher the frequency of
intra-amniotic infection by Ureaplasma urealyticum, My-
coplasma hominis, Gardnerella vaginalis, certain peptos-
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trepococci, and Bacteroides species (Yoon et al. 1999;
Peltier 2003). Interestingly, Watts et al. (1992) demonstrat-
ed that positive amniotic fluid cultures were present in 19%
of women with intact membranes with no clinical evidence
of intrauterine infection. It is well-known that inflammatory
processes trigger a wide range of uterus-contracting factors:
the influx of inflammatory cells into the uterus and elevated
levels of pro-inflammatory cytokines [tumor necrosis
factor-α (TNF-α), interleukin-1β, -6, -8], and prostaglan-
dins were observed in human amnion during parturition
(Lindström and Bennett 2005). The question is, whether
these processes promote uterus-relaxing mechanisms as well.
For this reason, in this study, we aimed to investigate
whether inflammatory processes affect the pharmacolog-
ical potency of β2-AR agonists. We set out to test the
uterus-relaxing potencies of β2-AR agonist terbutaline in
pregnant rats previously challenged with the intrauterine
administration of bacterial lipopolysaccharide (LPS), a by-
product mimicking an infection by Gram-negative bacteria
(Elovitz and Mrinalini 2004). Systemic inflammation was
followed-up by measurement of serum TNF-α levels. The
agonist-induced β2-AR activation was characterized by
the measurements of uterine Gs-protein activation and
cAMP accumulation.
Materials and methods
Animals
Animal investigations were carried out with the approval
of the Institutional Review Board (permission number I-
74-8/2002 issued by the Ethical Committee for Animal
Research at the University of Szeged).
Sexually mature female Sprague–Dawley rats (body
mass 140–160 g, 50–60 days old) were mated in the early
morning hours. Copulation was confirmed by the presence
of a copulation plug or spermatozoa in the vagina. The
day of conception was considered to be the first day of
pregnancy. The animals were housed in temperature- (20–
23°C), and humidity- (40–60%), and light- (12 h of light,
12 h of dark) regulated rooms with water and food intake
ad libitum.
In vivo treatments
Animals were divided into five groups (n=6–8 in each): (1)
nontreated controls; (2) LPS-treated; (3) sham-operated; (4)
LPS + thalidomide-treated; and (5) thalidomide-treated.
Nontreated controls (1) were intact, 21-day pregnant
rats. The administration of LPS was done on day 16 of
pregnancy (2). Rats were anesthetized with ketamine–
xylazin (45–5 mg/kg i.p.), then a midline abdominal
incision was made, and the uterine horns were exposed.
LPS (100 μg/kg per horn in physiological saline) was
carefully injected directly into the uterine lumen, into the gap
between the amniotic membranes (Elovitz and Mrinalini
2004). The incisions in the abdomen were closed by separate
surgical sutures, and the animals were kept under heating
light until awakening from narcosis. The sham-operated rats
(3) were injected with physiological saline into their uterine
lumen on day 16 of pregnancy. To a group of animals (4),
thalidomide (45 mg/kg; dissolved in 30% dimethyl-sulfoxide
in physiological saline) was given in a single i.p. injection,
30 min before the LPS treatment to inhibit tumor necrosis
factor-α (TNF-α) production (Giamarellos-Bourboulis et al.
2003). Another group (5) was treated with i.p. thalidomide
alone, on day 16 of pregnancy.
In vitro contractility studies
On day 21 of pregnancy, the rats were killed by CO2
inhalation at 12 A.M. (at preterm delivery), and the uteri
were removed and prepared for the in vitro contractility
assay as it was reported previously (Klukovits et al. 2004).
Briefly, the isolated uterine horns were immediately placed
in an organ bath (de Jongh solution; containing in mM: 137
NaCl, 3 KCl, 1 CaCl2, 1 MgCl2, 12 NaHCO3, 4 Na2HPO4,
6 glucose; pH 7.4) perfused with 95% oxygen and 5%
carbon dioxide; they were trimmed of fat, and the feto-
placental units were removed. Temperature was maintained
at 37°C. Four rings, 1 cm long, were sliced from the middle
part of each horn including implantation sites and tested in
parallel; they were mounted vertically between two plati-
num electrodes in the above-mentioned organ bath under
the same conditions. After mounting, the initial tension was
set at 1.5 g, and the rings were equilibrated for 90 min.
Then, rhythmic contractions were elicited by electric field
stimulation, performed by a digital, programmable stimula-
tor (ST-02, Experimetria, Budapest, Hungary). The square
pulse duration was set at 150 ms, periodic time at 24 s, and
the supramaximal voltage at 40 V (Gaspar et al. 2001).
After stimulation, terbutaline was added in noncumulative
manner. Between two concentrations of the drug, the
stimulation was suspended, tissues were washed extensive-
ly and allowed to recover. The tension of the myometrial
rings was measured with a strain gauge transducer (SG-02,
Experimetria, Budapest, Hungary) then recorded and
analyzed by SPEL Advanced ISOSYS Data Acquisition
System (Experimetria Ltd, Budapest, Hungary). The con-
traction inhibiting effects of terbutaline was expressed as
the percentage of the precontraction before each concentra-
tion, both characterized by the area under the curve of 4-
min periods. The relaxing potency of terbutaline in the
different groups of animals was compared on the basis of
the pD2 values (negative logarithm of the effective
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concentration 50; −logEC50). The pD2 values were calcu-
lated for each concentration–response curve individually.
Radioligand binding experiments
Radioligand binding experiments were carried out on 21-
day pregnant rat uterus membrane preparations. The uterine
tissues were cut and homogenized in buffer (0.01 M Tris–
HCl, 0.25 M sucrose, pH 8.0) with an Ultra-Turrax T25
homogenizer (Janke&Kunkel, IKA-Labortechnik Gmbh,
Straufen Germany), and centrifuged (20,000×g, 10 min,
4°C). The supernatants were stored at 4°C, and the pellets
were resuspended and recentrifuged. After mixing, the
supernatants were centrifuged (50,000×g, 60 min 4°C). The
pellets were resuspended and stored at −70°C.
The reaction mixture contained 100 μl membrane prepa-
ration (~0.5 mg/ml protein), 100 μl tritiated ß2-AR selective
ligand ([3H]ICI 118 551; Bilski et al. 1983) with a specific
activity of 18.8 Ci/mM, and 100 μl unlabeled ligand
(isoproterenol) for nonspecific binding or 100 μl incubation
buffer (consisting of 0.05 M Tris–HCl, 0.01 M MgCl2 and
2.5% ethanol, pH 7.42) for total binding. Protein was
determined by the method of Bradford (1976). Incubation
was started by addition of the membrane suspension and
continued in a shaking water bath until a steady state was
achieved (30°C, 30 min). At the end of the incubation, the
bound radioligand was separated from the residual-free
radioligand by rapid filtration on a Brandell cell harvester
(SEMAT, UK) through Whatman GF/C filters (SEMAT
Technical, St. Albans UK) and washed with 3×10 ml ice-
cold buffer (Tris–HCl, pH 7.42). The bound radioactivity was
determined in a HighSafe scintillation cocktail in a Wallac
1409 liquid scintillation counter (Wallac, Turku, Finland).
Saturation analysis of ß2-ARs was performed with [
3H]
ICI118,551 (0.5–10 nM) in the presence or absence of
1 μM unlabeled isoproterenol. Specific binding was
determined by subtracting the nonspecific binding from
the total binding values. All assays were carried out at least
three times in duplicate, and values are given as means±
SEM. Saturation experiments were individually analyzed,
the maximal numbers of binding sites (Bmax) and the
equilibrium dissociation constants (Kd) were calculated by
Scatchard transformation of saturation curves.
[35S]GTPγS binding assay
The uterine tissue samples obtained from 21-day pregnant
rats were homogenized, as it was reported previously
(Gaspar et al. 2005) and were diluted in 50 mM Tris–HCl
buffer (pH 7.4) to get appropriate protein content for the
assays (~10 μg of protein/sample). The membrane fractions
were incubated at 30°C for 60 min in Tris–EGTA buffer
(pH 7.4) composed of 50 mM Tris–HCl, 1 mM EGTA,
3 mM MgCl2, 100 mM NaCl, containing 20 MBq/0.05 ml
[35S]GTPγS (0.05 nM), and increasing concentrations of
terbutaline in the presence of excess GDP (30 μM) in a
final volume of 1 ml, according to Sim et al. (1995) and
Traynor and Nahorski (1995), with slight modifications.
Total binding (T) was measured in the absence of test
compound; nonspecific binding (NS) was determined in the
presence of 10 μM unlabeled GTPγS and subtracted from
total binding. The difference (T−NS) represents basal
activity. Bound and free [35S]GTPγS were separated by
vacuum filtration through Whatman GF/B filters (What-
man, Dassel, Germany) with Brandel M24R Cell harvester.
Filters were washed three times with 5 ml ice-cold buffer
(pH 7.4), and the radioactivity of the dried filters was
detected in UltimaGold™ F scintillation cocktail (Packard)
with Packard Tricarb 2300TR liquid scintillation counter.
Stimulation is given as percent of the specific [35S]GTPγS
binding observed in the absence of receptor ligands (basal
activity). [35S]GTPγS binding experiments were performed
in triplicates and repeated at least three times. Data were
analyzed by sigmoid dose–response curve fit option, pD2
values, and Emax values were also determined.
Measurement of uterine cAMP accumulation
Uterine tissue samples were incubated in de Jongh solution
(containing in mM: 137 NaCl, 3 KCl, 1 CaCl2, 1 MgCl2, 12
NaHCO3, 4 Na2HPO4, 6 glucose; pH 7.4) at 37°C, perfused
with the mixture of 95% oxygen and 5% CO2. Cyclic AMP
generation was stimulated with terbutaline for 10 min, in
the presence of the nonspecific phosphodiesterase inhibitor
3-isobutyl-1-methylxanthine (1 mM), then the samples
were immediately frozen in liquid nitrogen and stored there
until the extraction of cAMP (Sartori et al. 2002; Gaspar et
al. 2007). Then, frozen tissue samples were ground,
weighed, homogenized in ten volumes of ice-cold 5%
trichloroacetic acid and centrifuged at 600×g for 10 min.
The supernatants were extracted with three volumes of
water-saturated diethyl ether. After drying, the extracts were
stored at −70°C until the cAMP assay. Uterine cAMP
accumulation was measured with a commercial competitive
cAMP Enzyme Immunoassay (EIA) Kit (Sigma-Aldrich
Ltd, Budapest, Hungary), and tissue cAMP levels were
expressed in pmol/mg tissue.
Measurement of serum TNF-α level
On selected days of pregnancy (16, 17, 21), rats were
anesthetized with isoflurane, and blood samples were
taken by cardiac puncture. After centrifugation at 1,800×g
for 10 min, the sera were collected and stored at −70°C
until the TNF-α assay. Serum TNF-α concentrations were
determined by a commercial direct enzyme linked immu-
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noassay (ELISA) kit and were expressed as pg/ml. The
TNF-α ELISA Kit was manufactured by Biocompare and
was purchased from Izinta, (Budapest, Hungary).
Statistical analyses
All experiments were carried out on at least six animals,
and each value is given as a mean±SEM. All the curve
fittings (sigmoidal dose–response curves) and statistical
analyses were performed with the Prism 4.01 computer
software (Graph Pad Software, San Diego, CA, USA).
Group comparisons were made by one-way ANOVA tests
with Newman–Keuls posttest (pD2 value, maximal relax-
ing effect in the contractility assays, cAMP accumulation,
and serum TNF-α), and paired comparisons were made by
Student’s t test (Bmax, Kd in the receptor assays, pD2, and
maximal percent change in the [35S]GTPγS binding
assays).
Drugs
Terbutaline hemisulfate, isoproterenol hydrochloride, ket-
amine hydrochloride, xylazine hydrochloride, Escheri-
chia coli 055:B5 lipopolysaccharide, thalidomide, and
3-isobutyl-1-methylxanthine were purchased from Sigma-
Aldrich, Budapest, Hungary. [3H]ICI 118,551 (erythro-DL-
1(-methylindan-4-yloxy)-3-isopropylamino-butan-2-ol)
and [35S]GTPγS were purchased from Tocris Cookson,
Avonmouth, UK.
Results
Uterine activity was characterized by the AUC of electric
field (EF) stimulated contractions. Representative online
recordings of the in vitro motor activity of uterine ring
preparations from sham-operated (a), LPS-treated (b), and
LPS + thalidomide-treated (c) rats are presented in Fig. 1.
Neither LPS- nor LPS + thalidomide treatment altered
significantly the EF-stimulated rhythmic uterine contrac-
tions compared with the sham-operation (p>0.05 in both
comparisons; regarding the 4 min AUCs of all experi-
ments). In both the nontreated and the sham-operated
control rats, terbutaline concentration dependently inhibited
the rhythmic contractions of the isolated uterine rings
(Fig. 2). Neither the pD2 nor the maximal contraction-
inhibiting effects of terbutaline was found to differ
significantly in the sham-operated control group compared
with the nontreated control animals (p>0.05; Table 1). In
LPS-treated rats, however, the relaxing effect of terbutaline
was characterized by a significantly higher pD2 value
compared with either the nontreated (p<0.001) or the
sham-operated control rats (p<0.001), also shown by the
shift of the concentration–response curve to the left. In
LPS-treated rats, the maximal contraction-inhibiting effect
of terbutaline was not changed significantly (p>0.05).
To investigate the background of the enhanced potency
of the tested β2-adrenergic agonists, the uterine β2-AR
density was determined by radioligand binding technique.
The Scatchard analysis indicated (Fig. 3) that neither the
a
b
c
Fig. 1 Representative online
recordings of the in vitro motor
activity of uterine ring prepara-
tions from (a) sham-operated,
(b) LPS-treated, and (c) LPS +
thalidomide-treated rats. Con-
tractions were elicited by elec-
tric field stimulation (EFS; pulse
width 150 ms, periodic time
24 s, voltage 40 V) and the
contraction-inhibiting effects of
terbutaline was expressed as a
percentage of the precontraction
before each concentration, both
characterized by the area under
the curve of 4 min periods. S
with solid arrows the onset of
stimulation, dashed arrows the
addition of terbutaline, E with
dashed arrows end of stimula-
tion, W washing period
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Bmax of β2-ARs (in fmol/mg protein: 216.65±49.14 in the
nontreated and 263.40±15.27 in the LPS-treated group) nor
the Kd values (in nM: 1.41±0.07 in the nontreated and 1.51±
0.45 in the LPS-treated group) were significantly different
(p>0.05), which points to the similarity of both the maximum
number of binding sites and the binding affinities. No
significant change was found in the terbutaline-stimulated
[35S]GTPγS binding through the β2-ARs in LPS-treated and
nontreated rats (Fig. 4). Neither the pD2 values (8.21±0.41
in the nontreated and 8.04±0.35 in the LPS-treated group)
nor the maximal stimulation values (in percent: 110.8±2.5 in
the nontreated and 107.9±0.5 in the LPS-treated group) of
terbutaline on [35S]GTPγS binding were statistically differ-
ent (p>0.05). In this assay, [35S]GTPγS replaces endoge-
nous GTP and binds to the α subunit of G-protein, stabilizes
it, and then the accumulation of labeled Gα subunits can be
measured by counting the amount of 35S incorporated.
Terbutaline also concentration dependently enhanced the
uterine cAMP accumulation in the uteri of sham-operated
and LPS-treated rats (Fig. 5). Similarly as in the contrac-
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Fig. 2 Concentration–response curves of the action of terbutaline on
isolated uterine rings of nontreated, sham-operated, and LPS-treated
rats on day 21 of pregnancy. Intrauterine LPS treatment on day 16 of
pregnancy caused a marked shift to the left of the concentration–
response curve compared with the sham-operated controls, which
reveals an enhanced potency of terbutaline. The responses to each
concentration of terbutaline are expressed as the percentage inhibition
of the rhythmic contractions evoked by electric field stimulation,
where the activity of the uterine rings is characterized by the AUC.
Values are given as mean±SEM; n>6 in all cases
Table 1 The summary of the pD2 values and maximal contraction-
inhibiting effects of terbutaline on the isolated uteri of control and
differentially treated 21-day pregnant rats (n>6 in each group)
Animal group pD2 value Maximal contraction-
inhibiting effect (%)
Nontreated 7.37±0.11 85.21±7.54
Sham-operated 7.71±0.12 80.47±5.86
LPS-treated 9.14±0.36*** 67.19±4.28
LPS + THAL-treated 7.38±0.14 82.26±6.43
THAL-treated 7.53±0.29 73.36±4.52
LPS lipopolysaccharide, THAL thalidomide
***p<0.001 refers to the level of significant difference from all other
tested groups.
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Fig. 3 Representative saturation-binding curves of β2-adrenergic
receptors (β2-ARs) in the uteri of LPS-treated and nontreated rats,
on day 21 of pregnancy. Receptor bindings were determined with a
radioligand-binding technique using rat uterine membrane prepara-
tions. Saturation analysis of ß2-ARs was performed with [
3H]
ICI118,551 (0.5–10 nM) in the presence or absence of 1 μM
unlabeled isoproterenol. All assays were carried out at least three
times in duplicate, and values are given as means±SEM. Similarly
fitted curves reveal no alterations (p>0.05) in the maximum numbers
(Bmax) and the equilibrium dissociation constants (Kd) of the β2-ARs
in the uteri of LPS-treated compared with the nontreated control rats
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Fig. 4 Changes in [35S]GTPγS binding to uterine membranes in LPS-
treated and nontreated rats on day 21 of pregnancy by various
concentrations of terbutaline. The basal value is that of [35S]GTPγS
binding without terbutaline stimulation and was regarded as 100.
Points are means±SEM from three separate experiments carried out in
triplicate. Neither the maximal values nor the pD2 values of terbutaline
on [35S]GTPγS binding were statistically different (p>0.05)
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tility studies, the concentration–response curve of terbuta-
line on cAMP accumulation was shifted to the left in the
LPS-treated rats, with a significant rise in the pD2 (6.74±
0.26 in the sham-operated and 9.33±0.15 in the LPS-
treated group, p<0.05). It seems that the enhanced relaxing
potency of terbutaline is directly related to its enhanced
cAMP accumulating effect. Terbutaline induced the accu-
mulation of cAMP at similar concentrations to those that
evoked noteworthy relaxing effects on the uterine rings.
The ongoing inflammatory process was followed by the
measurement of serum TNF-α levels. Since thalidomide is
a known inhibitor of TNF-α production, we tested how a
single dose of thalidomide given prior to the intrauterine
LPS challenge affects blood TNF-α levels and whether it
affects the LPS-induced changes in the uterus relaxing
effects of terbutaline. The serum TNF-α level (Fig. 6) was
8.18±3.00 pg/ml in intact rats, on day 16 of pregnancy. On
day 17, sham-operation caused a slight but not significant
(p>0.05) rise of TNF-α level to 36.17±3.79 pg/ml, whereas
the intrauterine inoculation of LPS increased the serum
level of TNF-α to 179.60±36.92 pg/ml, which was
significantly (p<0.001) higher than in the sham operated
rats. Co-administration of thalidomide with LPS abolished
this rise of serum TNF-α concentration (9.53±4.61 pg/ml)
compared with the LPS treatment; in this group, there was
no statistical difference (p>0.05) from the sham-opera-
tion. On day 21, the serum TNF-α concentration was
significantly (p<0.05) higher in the LPS-treated rats
(122.20±24.92 pg/ml) than in either the sham-operated
rats (33.71±9.71 pg/ml) or in the LPS + thalidomide-
treated rats (46.40±7.97 pg/ml).
We also found that the inhibition of TNF-α synthesis by
thalidomide in the LPS-treated rats altered the uterus-
relaxing effect of terbutaline (Fig. 7). Thalidomide alone
had no effect on the concentration–response curve of
terbutaline; no significant change was found in the pD2
(p>0.05) or in the maximal inhibitory effect (p>0.05)
compared with the nontreated controls. In the LPS +
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Fig. 5 Concentration–response curves of the action of terbutaline on
uterine cAMP accumulation in LPS-treated and in sham-operated rats,
on day 21 of pregnancy. The cAMP levels were determined by
enzyme immunoassay. In LPS-treated rats, the curve is shifted to the
left which indicates that terbutaline elicits a similar rise in myometrial
cAMP levels at lower concentrations in LPS-treated rats compared
with the sham-operated rats. Values are given as mean±SEM; n=6 in
all groups
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Fig. 6 Serum TNF-α levels in intact rats (on day 16 of pregnancy),
and in sham-operated, LPS-treated and LPS + thalidomide-treated rats
on days 17 and 21 of pregnancy. On day 17, 24 h after LPS
inoculation, the serum TNF-α levels were significantly (***p<0.001)
increased in LPS-treated compared with the sham-operated rats.
Thalidomide given 30 min prior to LPS prevented the rise in the
serum TNF-α concentration which did not differ significantly from
that in the sham-operated rats (ns p>0.05). On day 21, the serum
TNF-α levels were still significantly higher (a p<0.05) in the LPS-
treated compared with the sham-operated rats. In rats that received
LPS+ thalidomide, the TNF-α concentration did not differ signifi-
cantly from that in the sham-operated rats (b p>0.05). Values are
given as means±SEM; n=6 in all groups
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thalidomide-treated rats, however, the pD2 of terbutaline
was similar to that of the sham-operated controls (p>0.05),
but at the same time, significantly lower than in rats treated
with LPS only (p<0.001). Thus, the co-administration of
thalidomide with LPS abolished the left shift of the
concentration–response curve of terbutaline. The pD2
values and the maximal inhibitory effects of terbutaline in
the thalidomide-treated groups are also listed in Table 1.
With regard to the uterine cAMP accumulation, the co-
administration of thalidomide with LPS also reversed the
LPS-induced change in the uterine cAMP accumulating
effect of terbutaline (Fig. 8). Similarly as in the contractility
studies, the concentration–response curve of terbutaline on
cAMP accumulation was similar to that of sham-operated
rats, without a significant rise in the pD2 values (6.74±0.26
in the sham-operated and 8.11±0.51 in the LPS +
thalidomide-treated group, p>0.05).
Discussion
Preterm delivery is one of the major determinants of infant
mortality and morbidity. The β2-AR agonists (ritodrine,
terbutaline, hexoprenaline) have an important role in the
management of preterm birth, although their therapeutic
efficacy is constantly being questioned. Recent articles
published in the Lancet or in the Cochrane Database of
Systematic Reviews approve that β2-AR agonists ritodrine
and terbutaline can delay delivery by 48 h (Iams et al.
2008; Withworth and Quenby 2008). However, there are
some concerns about their safety regarding unfavorable
side effects such as tachycardia and the risk of pulmonary
hypertension. Other treatment choices are the oxytocin
antagonist atosiban, magnesium sulfate, or the Ca2+
channel blocker nifedipin. Up-to-date evidences that
would support the use of magnesium sulfate as a tocolytic
are poor, and there are concerns about the effectiveness
and safety of atosiban and nifedipin as well (de Heus et al.
2008; Kam and Lamont 2008). Recent publications by a
group of scientists would promote the use of phosphodi-
esterase 4 inhibitors, especially in the case of intrauterine
inflammation, but clinical experiences are underway
(Méhats et al. 2007).
In our present study, we tested whether the long-standing
used β2-AR agonists have therapeutical benefit if preterm
uterine contractions were triggered by an inflammatory
process. Inflammation is believed to be a contributing
factor in many cases of preterm birth, and it often remains
unidentified. Obviously, there are some serious situations
(e.g., manifest chorioamnionitis) when preterm birth serves
the health of both the mother and the infant, but in most
cases, unfortunately, there are no such obvious reasons to
be detected. The main rationale for the use of tocolytic
drugs is to delay delivery until the mother is transferred to a
specialist unit which can increase the survival of preterm
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Fig. 7 Concentration–response curves of the action of terbutaline on
isolated uterine rings of the LPS-treated, LPS + thalidomide-treated,
and thalidomide-treated rats, and also those of the sham-operated and
nontreated controls on day 21 of pregnancy, respectively. The
administration of thalidomide alone did not change the effect of
terbutaline compared with nontreated controls. Thalidomide given
prior to the intrauterine LPS treatment in part prevented the LPS-
induced shift of the concentration–response curve to the left compared
with the sham-operated controls. The responses to each concentration
of terbutaline are expressed as the percentage inhibition of the
rhythmic contractions evoked by electric field stimulation, where the
activity of the uterine rings is characterized by the AUC. Values are
given as means±SEM; n>6 in all cases
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Fig. 8 Concentration–response curves of the action of terbutaline on
uterine cAMP accumulation in LPS-treated, LPS + thalidomide-
treated and sham-operated rats, on day 21 of pregnancy. The cAMP
levels were determined by enzyme immunoassay. Thalidomide
treatment prevented the LPS-induced left shift of the curve. Values
are given as means±SEM; n=6 in all groups
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infants due to obstetric interventions (screening for asymp-
tomatic bacteriuria, prophylactic antibiotic treatment for
group B streptococcal infections, and antenatal corticoste-
roid treatment; Iams et al. 2008).
Our results revealed that terbutaline has an enhanced
relaxing potency on the isolated uteri of the LPS-treated
rats. The pD2 value of terbutaline was significantly higher
in the case of inflammation, without meaningful changes in
the maximal relaxing effect, suggesting a change in some
receptor-mediated responses. Since the enhanced potency
of a pharmacologically active substance may be related
either to an increase in receptor number or to the
enhancement in post-receptorial signaling pathways, we
investigated the β2-AR density, the β2-AR-coupled G-
protein activation, and the agonist-stimulated cAMP accu-
mulation in the late-pregnant rat uterus. We detected that
neither the β2-AR density nor the affinity of terbutaline to
the β2-receptors was different in LPS-treated versus non-
treated rats. Furthermore, the activated G-protein-increasing
effect of terbutaline was also not significantly different in
LPS-treated versus nontreated rats. By this assay, we
measured the functional consequences of receptor occupan-
cy in one of the earliest receptor-mediated events (Harrison
and Traynor 2003).
Although the uterine inflammatory processes did not
affect the maximal G-protein activating property of terbuta-
line, it did change the local cAMP accumulation. By the
measurement of myometrial cAMP levels, we documented
that the concentration–response curve of terbutaline on
cAMP accumulation was shifted to the left in the LPS-
treated rats, with a significant rise in the pD2. It explains
why we could report an enhanced uterine relaxing effect of
terbutaline in the uteri of LPS-treated rats. For example,
10−8 M terbutaline elicited an approximately two times
greater effect in LPS-treated than in sham rats regarding
either the percentage of contraction inhibition or the uterine
cAMP accumulation. It seems that the local cAMP levels
well correlate with the in vitro effects of terbutaline.
Further, we looked for the possible reasons of the altered
β2-AR-mediated relaxation responses. Since previous
investigations have reported an increased cAMP signaling
in the presence of TNF-α in cultured human myometrial
cells (Gogarten et al. 2003), we hypothesized that the
generation of some inflammatory mediators leads to the
enhanced synthesis of cAMP and the increased relaxing
potency of β2-AR agonists in the uterus. For this reason,
serum TNF-α levels were measured before and after the
inoculation of LPS, and rats were pretreated with thalido-
mide, a known inhibitor of TNF-α synthesis (Combe 2001;
Kim et al. 2004), prior to the LPS treatment, and the uteri of
this group were also tested in the contractility assays and
for cAMP accumulation. We note here that the single dose
of thalidomide given on day 16 was indicated merely for
theoretical purposes, to study a possible link between TNF-
α and the myometrial cAMP generation.
Thalidomide administration abolished the LPS-evoked
rise in serum TNF-α concentration at 24 h, and its
diminishing effect on TNF-α levels was still detectable at
the time of preterm parturition. Moreover, thalidomide
prevented in part the left-shift of the concentration–
response curve of terbutaline in LPS-treated rats in the
contractility as well as the cAMP accumulation assays.
Thus, by the inhibition of TNF-α synthesis in the LPS-
treated animals, the potentiation of the relaxing effect or
cAMP-accumulating effect of terbutaline is nearly abol-
ished which promotes the role of TNF-α in altered
signaling through β2-ARs.
A possible explanation for the TNF-α-related changes in
uterine cAMP levels might be the adenylyl cyclase
sensitization in the myometrial plasma membrane. Osawa
et al. (2007) reported recently that, in human airway smooth
muscle cells, chronic exposure to TNF-α, by the trans-
activation of epidermal growth factor receptors, induces a
raf-1 kinase-mediated phosphorylation and activation of the
adenylyl cyclase enzyme, leading to a “cAMP overshoot.”
That kind of adenylyl cyclase sensitization, which does not
affect receptor binding or Gs protein activation, might be
responsible for the altered cAMP-mediated relaxation
processes in the rat myometrium as well.
Our finding that the inflammatory processes augment the
cAMP-mediated relaxation in the rat uterus is novel, since
previous studies reported opposite regulation of β2-AR-
mediated responses by inflammatory processes. In the
mouse airways, IL-1β and TNF-α induce desensitization
(phosphorylation) of the β2-ARs and decrease cAMP levels
(Guo et al. 2005). In the pregnant rat uterus, however, we
demonstrated that inflammatory mediators might be able to
stimulate the synthesis of cAMP. We concluded that the
LPS-induced elevation of the serum TNF-α level probably
plays an important role in the altered responsiveness to β2-
AR activation. TNF-α is probably not the only cytokine
involved in this regulatory process, but it has been proved
to be a meaningful one.
Nevertheless, local cAMP levels in the myometrium
cells are also regulated by the cyclic nucleotide phospho-
diesterases (PDEs) which hydrolyze cAMP to inactive 5′-
AMP. Any change in PDE expression or activity may alter
cAMP-mediated relaxation responses in the myometrium.
We think, however, that measuring PDE activity or
detecting the changes in the expressions of several known
PDE isoforms in the rat myometrium would go far beyond
the limits of this paper. At the same time, we wish to
mention that, in a recent study, no change was observed in
the PDE activity and PDE4B2 expression in the uterine
tissues of LPS-challenged pregnant mice (Schmitz et al.
2007). Here, we intended to focus on the possible
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alterations of the β2-adrenergic receptor-mediated uterus
relaxation in the late-pregnant rat uterus in inflammatory
conditions, as well as receptor binding, receptor-coupled G-
protein activation, and cAMP accumulation.
To summarize the above findings, our results reveal an
altered responsiveness of the rat myometrium to β2-AR
agonists in consequence of intrauterine inflammation.
Although the inflammation itself does not alter the β2-AR
density, it may lead to changes in the Gs-coupled adenylyl
cyclase activity and enhanced myometrial cAMP accumu-
lation. Although the enhanced relaxing potency of β2-
agonists is a consequence of a pathological condition, it
may become beneficial with regard to tocolytic therapy.
The enhanced potency of β2-agonists may promote the
administration of lower doses, which would be equally
effective in relaxing the uterus, thereby avoiding the early
onset of side effects and delaying the homologous
desensitization of β2-ARs that limits the long-term admin-
istration of β2-agonists. Besides, there are evidences that
the β2-AR agonists possess anti-inflammatory properties
which is cAMP- and protein kinase A-dependent (Farmer
and Pugin 2000; Maris et al. 2005). The anti-inflammatory
effect of a tocolytic drug is of a great value because it may
relieve a silent but ongoing inflammation and prolong
pregnancy. The therapeutic strategy for the prevention of
preterm births that might have inflammatory origin should
focus on agents which can inhibit early uterine contractions
and also able to control inflammation and its consequences
for the mother and infant. According to the present
findings, the β2-AR agonists have an enhanced uterus
relaxant effect after an LPS challenge, and they also have
anti-inflammatory properties. Detection of the underlying
causes of preterm labor contractions is not an easy task,
though interventions might be more specific and effective if
the ongoing inflammatory process is diagnosed.
Acknowledgments This work was supported financially by National
Council for Research and Technology (NKFP) Budapest (RET 08/2004).
We thank Zsuzsanna Magyar, Zsuzsanna Tóth, and Adrienn Gál for their
technical assistance in the experiments.
References
BerkmanND, Thorp JM Jr, Lohr KN, Carey TS, Hartmann KE, GavinNI
(2003) Tocolytic treatment for the management of preterm labor: a
review of the evidence. Am J Obstet Gynecol 188:1648–1659
Bilski AJ, Halliday SE, Fitzgerald JD, Wale JL (1983) The
pharmacology of a beta 2-selective adrenoceptor antagonist (ICI
118,551). J Cardiovasc Pharmacol 5:430–437
Bradford MM (1976) A rapid and sensitive method for the
quantitation of microgram quantities of protein utilizing the
principle of protein-dye binding. Anal Biochem 72:248–254
Challis JRG, Matthews SG, Gibb W, Lye SJ (2000) Endocrine and
paracrine regulation of birth at term and preterm. Endocr Rev
21:514–550
Challis JR, Sloboda DM, Alfaidy N, Lye SJ, Gibb W, Patel FA (2002)
Prostaglandins and mechanisms of preterm birth. Reproduction
124:1–17
Combe B (2001) Thalidomide: new indications? Joint Bone Spine
68:582–587
de Heus R, Mulder EJ, Derks JB, Visser GH (2008) Acute tocolysis
for uterine activity reduction in term labor—a review. Obstet
Gynecol Surv 63:383–388
Elovitz MA, Mrinalini C (2004) Animal models of preterm birth.
Trends Endocrinol Metab 15:479–487
Farmer P, Pugin J (2000) beta-Adrenergic agonists exert their “anti-
inflammatory” effects in monocytic cells through the IkappaB/
NF-kappaB pathway. Am J Physiol Lung Cell Mol Physiol 279:
L675–682
Garfield RE, Saade G, Buhimschi C, Buhimschi I, Shi L, Shi SQ,
Chwalisz K (1998) Control and assessment of the uterus and cervix
during pregnancy and labour. Hum Reprod Update 4:673–695
Gaspar R, Foldesi I, Havass J, Marki A, Falkay G (2001) Character-
ization of late-pregnant rat uterine contraction via the contractility
ratio in vitro significance of alpha1-adrenoceptors. Life Sci
68:1119–1129
Gaspar R, Ducza E, Mihalyi A, Marki A, Kolarovszki-Sipiczki Z,
Paldy E, Benyhe S, Borsodi A, Foldesi I, Falkay G (2005)
Pregnancy-induced decrease in the relaxant effect of terbutaline
in the late-pregnant rat myometrium: role of G-protein activation
and progesterone. Reproduction 130:113–122
Gaspar R, Gal A, Galik M, Ducza E, Minorics R, Kolarovszki-
Sipiczki Z, Klukovits A, Falkay G (2007) Different roles of
alpha2-adrenoceptor subtypes in non-pregnant and late-pregnant
uterine contractility in vitro in the rat. Neurochem Int 51:311–318
Giamarellos-Bourboulis EJ, Poulaki H, Kostomitsopoulos N, Dontas I,
Perrea D, Karayannacos PE, Giamarellou H (2003) Effective
immunomodulatory treatment of Escherichia coli experimental
sepsis with thalidomide. Antimicrob Agents Chemother 47:
2445–2449
Gogarten W, Lindeman KS, Hirshman CA, Emala CW (2003) Tumor
necrosis factor alpha stimulates adenylyl cyclase activity in
human myometrial cells. Biol Reprod 68:751–757
Goldenberg RL, Hauth JC, Andrews WW (2000) Intrauterine
infection and preterm delivery. N Engl J Med 342:1500–1507
GuoM, Pascual RM,Wang S, FontanaMF, Valancius CA, Panettieri RA,
Tilley SL, Penn RB (2005) Cytokines regulate β2-adrenergic
receptor responsiveness in airway smooth muscle via multiple
PKA- and EP2-receptor mediated mechanisms. Biochem 44:
13771–13782
Harrison C, Traynor JR (2003) The [35S]GTPgammaS binding assay:
approaches and applications in pharmacology. Life Sci 74:489–508
Iams JD, Romero R, Culhane JF, Goldenberg RL (2008) Primary,
secondary, and tertiary interventions to reduce the morbidity and
mortality of preterm birth. Lancet. 371:164–175
Kam KY, Lamont RF (2008) Developments in the pharmacother-
apeutic management of spontaneous preterm labor. Expert Opin
Pharmacother 9:1153–1168
Kim YS, Kim JS, Jung HC, Song IS (2004) The effects of thalidomide
on the stimulation of NF-kappaB activity and TNF-alpha
production by lipopolysaccharide in a human colonic epithelial
cell line. Mol Cells 17:210–216
Klukovits A, Gáspár R, Sántha P, Jancsó G, Falkay G (2004) Role of
capsaicin-sensitive nerve fibers in uterine contractility in the rat.
Biol Reprod 70:184–190
Lindström TM, Bennett PR (2005) The role of nuclear factor kappa B
in human labor. Reproduction 130:569–581
Maris NA, de Vos AF, Dessing MC, Spek CA, Lutter R, Jansen HM,
van der Zee JS, Bresser P, van der Poll T (2005) Antiinflamma-
tory effects of salmeterol after inhalation of lipopolysaccharide
by healthy volunteers. Am J Respir Crit Care Med 172:878–884
Naunyn-Schmied Arch Pharmacol (2009) 379:501–510 509
Méhats C, Schmitz T, Oger S, Hervé R, Cabrol D, Leroy MJ (2007)
PDE4 as a target in preterm labour. BMC Pregnancy Childbirth 7
(Suppl 1):S12
Osawa Y, Yim PD, Xu D, Panettieri RA, Emala CW (2007) Raf-1
kinase mediates adenylyl cyclase sensitization by TNF-alpha in
human airway smooth muscle cells. Am J Physiol Lung Cell Mol
Physiol 292:L1414–1421
Peltier MR (2003) Immunology of term and preterm labor. Repro-
ductive Biology and Endocrinology 1:122–132
Romero R, Mazor M, Wu YK, Sirtori M, Oyarzun E, Mitchell MD,
Hobbins JC (1988) Infection in the pathogenesis of preterm labor.
Semin Perinatol 12:262–279
Sartori C, Fang X, McGraw DW, Koch P, Snider ME, Folkesson HG,
Matthay MA (2002) Lung edema clearance: 20 years of progress.
Selected contribution: long-term effects of β2-adrenergic receptor
stimulation on alveolar fluid clearance in mice. J Appl Physiol
93:1875–1880
Schmitz T, Souil E, Hervé R, Nicco C, Batteux F, Germain G, Cabrol D,
Evain-Brion D, Leroy MJ, Méhats C (2007) PDE4 inhibition
prevents preterm delivery induced by an intrauterine inflammation.
J Immunol 178:1115–1121
Sim LJ, Selley DE, Childers SR (1995) In vitro autoradiography of
receptor-activated G proteins in rat brain by agonist-stimulated
guanylyl 5′-[gamma-[35S]thio]-triphosphate binding. Proc Natl
Acad Sci USA 92:7242–7246
Smith GN (2003) What are the realistic expectations of tocolytics?
BJOG 20:103–106
Traynor JR, Nahorski SR (1995) Modulation by mu-opioid agonists of
guanosine-5′-O-(3-[35S](thio)triphosphate binding to membranes
from human neuroblastoma SH-SY5Y cells. Molecular Pharma-
cology 47:848–854
Watts DH, Krohn MA, Hillier SL, Eschenbach DA (1992) The
association of occult amniotic fluid infection with gestational age
and neonatal outcome among women in preterm labor. Obstet
Gynecol 79:351–357
Withworth M, Quenby S (2008) Prophylactic oral betamimetics for
preventing preterm labour in singleton pregnancies. Cochrane
Database Syst Rev 23:CD006395
Wray S, Kupittayanant S, Shmygol A, Smith RD, Burdyga T (2001)
The physiological basis of uterine contractility: a short review.
Exp Physiol 86:239–246
Yoon BH, Kim YA, Romero R, Kim JC, Park KH, Kim MH, Park JS
(1999) Association of oligohydramnios in women with preterm
premature rupture of membranes with an inflammatory response
in fetal, amniotic, and maternal compartments. Am J Obstet
Gynecol 181:784–788
510 Naunyn-Schmied Arch Pharmacol (2009) 379:501–510
